HLS Therapeutics (HLS) Resumen de Acciones
HLS Therapeutics Inc, empresa farmacéutica especializada, adquiere y comercializa productos farmacéuticos para el tratamiento de trastornos psiquiátricos, del sistema nervioso central y enfermedades cardiovasculares en Canadá, Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
HLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de HLS Therapeutics Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | CA$3.90 |
| Máximo en las últimas 52 semanas | CA$5.77 |
| Mínimo de 52 semanas | CA$3.77 |
| Beta | 0.86 |
| Cambio en 1 mes | -5.11% |
| Variación en 3 meses | -15.03% |
| Cambio de 1 año | -23.15% |
| Variación en 3 años | -20.41% |
| Variación en 5 años | -77.71% |
| Variación desde la OPV | -66.35% |
Noticias y actualizaciones recientes
Artículo de análisis • 16h
HLS Therapeutics Inc. (TSE:HLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
HLS Therapeutics Inc. ( TSE:HLS ) defied analyst predictions to release its quarterly results, which were ahead of...
Actualización de narrativa • Aug 14
HLS: Inflection Point In Cash Generation Will Drive Positive Momentum
Analysts lifted their 12 month price target for HLS Therapeutics to CA$8 from CA$7, citing recent rating upgrades and research that describe the company as reaching an inflection point with a stronger growth and cash generation profile. Analyst Commentary Recent research on HLS Therapeutics highlights a shift in tone, with several firms now framing the company as being at an inflection point.Recent updates
Artículo de análisis • 16h
HLS Therapeutics Inc. (TSE:HLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
HLS Therapeutics Inc. ( TSE:HLS ) defied analyst predictions to release its quarterly results, which were ahead of...Actualización de narrativa • Aug 14
HLS: Inflection Point In Cash Generation Will Drive Positive Momentum
Analysts lifted their 12 month price target for HLS Therapeutics to CA$8 from CA$7, citing recent rating upgrades and research that describe the company as reaching an inflection point with a stronger growth and cash generation profile. Analyst Commentary Recent research on HLS Therapeutics highlights a shift in tone, with several firms now framing the company as being at an inflection point.
Actualización de narrativa • Jun 23
HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance
Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.
Actualización de narrativa • Jun 07
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.Actualización de narrativa • May 24
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.Actualización de narrativa • May 04
HLS: Future Upside Will Depend On Executing Refined Earnings Outlook
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company that feed into revised assumptions regarding growth, margins and future P/E. Analyst Commentary Recent research updates on HLS Therapeutics show price targets aligning at CA$4.45, with ratings maintained rather than shifted to more negative stances.Actualización de narrativa • Apr 18
HLS: Future Execution Risks Will Temper Benefits Of New Cholesterol Franchise
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on its growth profile and profitability. Analyst Commentary Bearish analysts are signaling a more cautious stance on HLS Therapeutics after the revised CA$4.45 price target.Actualización de narrativa • Apr 02
HLS: Future Execution Risks Will Offset New Product And Margin Assumptions
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company’s revenue growth potential, profit margin outlook, and a higher assumed future P/E multiple. Analyst Commentary Bearish analysts have reacted to recent developments by trimming their price target on HLS Therapeutics to CA$4.45 from CA$4.75, while maintaining a Hold stance.Actualización de narrativa • Mar 18
HLS: Future Share Performance Will Rely On Execution Against Updated Outlook
The analyst price target for HLS Therapeutics has been reduced by CA$0.30 to CA$4.45. Analysts cited updated assumptions around growth, profitability and valuation multiples as key drivers for the change.Actualización de narrativa • Mar 03
HLS: Fair Outlook Will Balance Revised Profitability Assumptions And Execution Risks
Analysts have trimmed their price target on HLS Therapeutics to CA$4.72 from CA$4.76, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a slightly lower future P/E multiple. Valuation Changes Fair Value: CA$ fair value estimate adjusted slightly from CA$4.76 to CA$4.72.Actualización de narrativa • Feb 17
HLS: Improved Profitability Outlook Will Support Stronger Future Share Performance
Analysts now see fair value for HLS Therapeutics at about CA$11.59, slightly below the prior CA$11.79. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.Actualización de narrativa • Feb 03
HLS: Higher Profitability Outlook Will Support Upgraded Future Share Performance
Analysts have nudged their price target on HLS Therapeutics higher to C$7 from C$6, pointing to updated assumptions on revenue growth, profit margins and future P/E levels that support a slightly revised outlook for the shares. Analyst Commentary Recent Street research reflects a slightly more optimistic tone around HLS Therapeutics, with bullish analysts adjusting their models to support a higher valuation anchor for the shares.Actualización de narrativa • Jan 20
HLS: Higher Profitability Outlook Will Drive Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics to C$7 from C$6, reflecting updated views on fair value, growth expectations, profitability, and future P/E assumptions. Analyst Commentary Recent Street research points to a more constructive view on HLS Therapeutics, with bullish analysts revisiting their assumptions on fair value, growth potential, and what they are willing to pay on a P/E basis.Actualización de narrativa • Jan 06
HLS: Higher Rating Outlook Will Balance Execution Risks And Near Term Guidance
Analysts lifted their price target for HLS Therapeutics to C$7 from C$6, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and a lower future P/E multiple in their models. Analyst Commentary Even with the price target now set at C$7, some research commentary still reads as cautious.Actualización de narrativa • Dec 14
HLS: Higher Projected Earnings Will Support Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics by C$1 to C$7, reflecting higher projected fair value, faster expected revenue growth, and improved profit margin assumptions, despite a slightly higher discount rate and lower future P/E multiple. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in HLS Therapeutics execution and earnings trajectory, even after factoring in a modestly higher risk profile.Actualización de narrativa • Nov 19
HLS: Ongoing Share Buybacks And Debt Reduction Will Drive Positive Momentum
The analyst price target for HLS Therapeutics has increased from C$6 to C$7. This reflects analysts’ confidence in the company’s improving financial performance and ongoing strategic initiatives.Artículo de análisis • Nov 16
HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target
The analysts might have been a bit too bullish on HLS Therapeutics Inc. ( TSE:HLS ), given that the company fell short...Actualización de narrativa • Sep 25
Canadian Regulatory Approvals Will Foster A Vibrant Cardiovascular Market
Analysts have raised their price target for HLS Therapeutics to CA$7.41, citing positive impacts from share buybacks, debt reduction, and an expanding product portfolio, alongside signs of adjusted EBITDA recovery and improved operational performance. Analyst Commentary Share buybacks and debt reduction are viewed positively for capital allocation and balance sheet strength.
Nueva narrativa • Apr 07
Vascepa Sales In Canada And Cost Cuts Will Transform Prospects
Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.Artículo de análisis • Oct 26
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, HLS Therapeutics fair value estimate is CA$6.42 Current share...Artículo de análisis • Sep 28
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
It's not a stretch to say that HLS Therapeutics Inc.'s ( TSE:HLS ) price-to-sales (or "P/S") ratio of 1.5x right now...Artículo de análisis • May 12
Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
It's shaping up to be a tough period for HLS Therapeutics Inc. ( TSE:HLS ), which a week ago released some...Artículo de análisis • Apr 14
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
The HLS Therapeutics Inc. ( TSE:HLS ) share price has done very well over the last month, posting an excellent gain of...Artículo de análisis • Apr 06
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Nov 16
Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Market forces rained on the parade of HLS Therapeutics Inc. ( TSE:HLS ) shareholders today, when the analysts...Artículo de análisis • Sep 13
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rentabilidad de los accionistas
| HLS | CA Pharmaceuticals | Mercado CA | |
|---|---|---|---|
| 7D | -3.2% | -1.4% | 1.0% |
| 1Y | -23.2% | -2.1% | 31.7% |
Rentabilidad vs. Industria: Los resultados de HLS fueron inferiores a los de la industria Canadian Pharmaceuticals, que obtuvo un rendimiento del -2.1% el año pasado.
Rentabilidad vs. Mercado: HLS obtuvo unos resultados inferiores a los del mercado Canadian, que fueron del 31.7% el año pasado.
Volatilidad de los precios
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in CA Market | 16.4% |
| 10% least volatile stocks in CA Market | 3.7% |
Precio estable de las acciones: HLS no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Canadian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HLS (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 85 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc, una empresa farmacéutica especializada, adquiere y comercializa productos farmacéuticos para el tratamiento de trastornos psiquiátricos, del sistema nervioso central y enfermedades cardiovasculares en Canadá, Estados Unidos y a escala internacional. Los principales productos de la empresa son Clozaril, un antipsicótico atípico para el tratamiento de los síntomas de la esquizofrenia resistente al tratamiento, y Vascepa, cápsulas de icosapent etílico para enfermedades cardiovasculares. También distribuye los ensayos de laboratorio MyCare para psiquiatría y MyCare Insite, un dispositivo para medir los niveles de fármacos en los pacientes.
Resumen de fundamentos de HLS Therapeutics Inc.
| Estadísticas fundamentales de HLS | |
|---|---|
| Capitalización bursátil | CA$121.97m |
| Beneficios(TTM) | -CA$11.89m |
| Ingresos (TTM) | CA$78.05m |
1.6x
Ratio precio-ventas (PS)-10.3x
Ratio precio-beneficio (PE)¿Está HLS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HLS | |
|---|---|
| Ingresos | US$56.24m |
| Coste de los ingresos | US$16.83m |
| Beneficio bruto | US$39.41m |
| Otros gastos | US$47.98m |
| Beneficios | -US$8.57m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.27 |
| Margen bruto | 70.07% |
| Margen de beneficio neto | -15.24% |
| Ratio deuda/patrimonio | 85.2% |
¿Cómo se ha desempeñado HLS a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/16 06:09 |
| Precio de las acciones al final del día | 2026/08/14 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
HLS Therapeutics Inc. está cubierta por 4 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |